Is CD49f a reliable marker for reactive astrocytes?
Best insight from top research papers
CD49f is indeed a reliable marker for reactive astrocytes, as indicated by research findings. It has been demonstrated that CD49f is an effective surface marker for sorting functional human astrocytes, enabling the isolation of astrocytes from complex central nervous system cell populations . Moreover, studies have shown that CD49f expression varies among genetic subgroups of B lymphoblastic leukemia, with significantly lower expression in certain cases, highlighting its specificity as a marker . In the context of colorectal cancer, CD49f has been identified as an important marker for identifying cancer stem cells, particularly colorectal cancer stem cells, emphasizing its significance in disease characterization and treatment development . Therefore, based on the evidence from various studies, CD49f emerges as a valuable and reliable marker for differentiating and studying reactive astrocytes and other cell types in various pathological conditions.
Answers from top 4 papers
More filters
| Papers (4) | Insight |
|---|---|
| Not addressed in the paper. | |
| Yes, CD49f is a reliable marker for reactive astrocytes as it can isolate functional astrocytes that exhibit an A1 neurotoxic phenotype, secreting pro-inflammatory cytokines and showing impaired neuronal support. | |
10 Nov 2020 6 Citations | CD49f is a reliable marker for isolating human astrocytes, including reactive astrocytes, from various cell sources, aiding in neurotoxicity assays and studies on astrocyte biology. |
| Not addressed in the paper. |
Related Questions
What is the specific role of FAM49(CYRI) in the development and progression of atherosclerosis?5 answersFAM49, also known as CYRI, plays a crucial role in atherosclerosis development and progression. CYRI acts as a regulator of actin-based protrusions by binding to activated Rac1, influencing lamellipodia dynamics. Its depletion leads to broad lamellipodia and altered protrusion-retraction dynamics, while overexpression suppresses productive protrusions. In the context of atherosclerosis, abnormalities in glycolytic flux accelerate disease progression. Furthermore, atherosclerosis is driven by inflammation mediated by cytokines, where pro-inflammatory cytokines exacerbate the disease, while anti-inflammatory cytokines ameliorate it. Therefore, CYRI's role in regulating protrusion dynamics and its interaction with Rac1 may impact the inflammatory processes and plaque formation associated with atherosclerosis.
How are reactive astrocytes involved in neurodegeneration?5 answersReactive astrocytes play a crucial role in neurodegeneration by adopting a neurotoxic phenotype in response to various triggers like aging, injury, or neuroinflammation. These astrocytes, termed A1, A1-like, or neuroinflammatory reactive astrocytes, downregulate supportive functions and start secreting neurotoxic factors, complement components, and chemokines, potentially facilitating immune cell recruitment into the central nervous system. Single-cell transcriptomics have revealed the heterogeneity of reactive astrocytes across different neuropathologies, indicating their multifaceted functions in neurotrauma, stroke, and neurodegenerative diseases. Additionally, astrocytes secrete lipocalin-2 (LCN2), which can lead to neurodegeneration after stroke, with NADPH oxidase (NOX) signaling and ROS-mediated mechanisms playing a role in LCN2 expression and secretion. The binding of 11C‐Deuterium‐L‐Deprenyl PET (DED) can be used to measure reactive astrocytes in various dementia disorders, highlighting their association with neuroinflammation and neurodegeneration.
Cd47 role in the brain?5 answersCD47 is a receptor belonging to the immunoglobulin superfamily and is broadly expressed on cell membranes. It regulates various functions in the body, including cell adhesion, proliferation, apoptosis, migration, and the immune system. CD47 has been found to modulate phagocytosis via macrophages, transmigration of neutrophils, and activation of T-cells, dendritic cells, and B-cells. In the context of neurodegenerative disorders, CD47 has been implicated in the development of different pathologies in the central nervous system (CNS). Additionally, CD47 has been shown to play a role in brain overgrowth, as it is overexpressed in carriers of the 16p11.2 deletion, contributing to reduced phagocytosis of neural progenitor cells and oligodendrocyte progenitor cells. Furthermore, CD47 has been found to mediate immune evasion in glioblastomas, preventing phagocytosis of tumor cells by macrophages and other myeloid cells. The role of CD47 in adamantinomatous craniopharyngioma (ACP) is still unclear. Overall, CD47 plays a significant role in various brain-related processes and diseases.
Is cd49f a useful marker for BCP-ALL MRD?5 answersCD49f is a useful marker for minimal residual disease (MRD) detection in T-lineage acute lymphoblastic leukemia (T-ALL). It has been shown that CD99, another marker, is also effective in quantifying T-ALL MRD. However, CD49f has the advantage of surface expression, unlike CD99 which is intracellular. CD49f expression on leukemic lymphoblasts is significantly higher than on normal T lymphocytes, making it a reliable marker for MRD assessment. CD49f can be used to sort functional human astrocytes, which play a crucial role in the central nervous system. It has been demonstrated that CD49f+ astrocytes perform key astrocytic functions and can acquire an A1-like reactive state in response to inflammatory stimuli. However, there is no specific mention of CD49f as a marker for B-cell precursor acute lymphoblastic leukemia (BCP-ALL) MRD in the provided abstracts.
What is the role of CD49d in Cd4 T cells?5 answersCD49d is a marker expressed on specific CD4+ T cells. It is upregulated upon activation and can be used as a marker for antigen-specific Th1 CD4+ T cells. CD4 T cells have been largely neglected in cancer immunotherapy due to the lack of MHC II expression on most cancers. However, tumor antigens can be captured and cross-presented by MHC II-expressing tumor stromal cells, allowing CD4 T cells to play a role in tumor immunity. CD11a and CD49d have been shown to be markers of antigen-specific CD4 and CD8 T cell responses following T cell-targeted vaccination. In type 2 diabetes mellitus patients, the frequency and suppressive potency of CD49d- Treg cells, a subset of CD4+ T cells, are reduced, leading to a failure to inhibit aggressive inflammatory responses.
What is the overlap between astrocyte and microglial markers in epilepsy?3 answersAstrocyte and microglial markers in epilepsy show some overlap. In patients with epilepsy, astrocytes were found to express glial fibrillary acidic protein (GFAP). Additionally, astrocytes were positive for purinergic receptor subtypes P2RY1, P2RY2, P2RY4, potassium channels Kv4.2 and Kir4.1, and metabotropic receptor subtypes mGluR1 and mGluR5. These markers indicate the involvement of astrocytes in astrocyte transmission, neuron-glia network formation, and other physiological functions. On the other hand, microglia, another type of glial cell, have been implicated in the pathophysiology of epilepsy. Microglia, particularly activated microglia, have been shown to contribute to the imbalance between excitatory and inhibitory neurotransmission in epilepsy. Therefore, both astrocytes and microglia play important roles in epilepsy, with astrocytes showing overlap in markers associated with their activation and function, and microglia contributing to the pathophysiology of the disorder.